Viking Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.76 Insider Own0.20% Shs Outstand76.84M Perf Week12.58%
Market Cap254.57M Forward P/E- EPS next Y-1.03 Insider Trans46.29% Shs Float67.77M Perf Month-0.83%
Income-59.10M PEG- EPS next Q-0.23 Inst Own41.40% Short Float3.20% Perf Quarter61.26%
Sales- P/S- EPS this Y-30.90% Inst Trans-0.79% Short Ratio1.88 Perf Half Y-4.02%
Book/sh2.15 P/B1.67 EPS next Y-15.60% ROA-29.10% Target Price17.56 Perf Year-40.03%
Cash/sh2.38 P/C1.51 EPS next 5Y40.00% ROE-31.00% 52W Range2.02 - 7.20 Perf YTD-22.17%
Dividend- P/FCF- EPS past 5Y4.70% ROI- 52W High-50.28% Beta1.38
Dividend %- Quick Ratio12.10 Sales past 5Y- Gross Margin- 52W Low77.23% ATR0.27
Employees17 Current Ratio12.10 Sales Q/Q- Oper. Margin- RSI (14)59.24 Volatility7.15% 7.91%
OptionableYes Debt/Eq0.00 EPS Q/Q-14.90% Profit Margin- Rel Volume0.29 Prev Close3.61
ShortableYes LT Debt/Eq0.00 EarningsJul 27 AMC Payout- Avg Volume1.15M Price3.58
Recom1.60 SMA207.31% SMA5022.18% SMA200-2.20% Volume329,998 Change-0.83%
Jul-29-21Resumed BTIG Research Buy $20
May-25-21Downgrade Raymond James Strong Buy → Outperform $27 → $12
Jun-05-20Initiated BMO Capital Markets Outperform $14
May-05-20Initiated Chardan Capital Markets Buy $15
May-01-20Initiated BTIG Research Buy $9
Jul-16-19Initiated Oppenheimer Outperform $12
Jun-25-19Initiated Stifel Buy
Mar-29-19Upgrade SVB Leerink Mkt Perform → Outperform $10 → $21
Mar-14-19Reiterated Maxim Group Buy $28 → $20
Feb-22-19Initiated SVB Leerink Mkt Perform
Dec-12-18Initiated B. Riley FBR Buy $16
Nov-19-18Upgrade Raymond James Outperform → Strong Buy
Sep-18-18Reiterated Raymond James Outperform $15 → $43
Sep-18-18Reiterated Maxim Group Buy $14 → $28
Sep-18-18Reiterated H.C. Wainwright Buy $15 → $28
Jul-20-18Initiated SunTrust Buy $14
Jun-28-18Initiated Raymond James Outperform
Jun-01-18Reiterated Laidlaw Buy $10 → $15
May-31-18Reiterated Maxim Group Buy $8 → $14
Mar-26-18Resumed H.C. Wainwright Buy $11
Aug-05-22 06:51AM  
Aug-02-22 04:05PM  
Jul-28-22 12:30AM  
Jul-27-22 04:05PM  
Jul-20-22 04:02PM  
Jul-19-22 10:44AM  
Jul-06-22 04:05PM  
Jun-07-22 10:06AM  
Jun-06-22 12:19PM  
May-27-22 01:34PM  
May-16-22 04:05PM  
May-11-22 08:59AM  
Apr-29-22 03:00PM  
Apr-28-22 12:30AM  
Apr-27-22 04:08PM  
Apr-22-22 11:36AM  
Apr-20-22 04:05PM  
Apr-06-22 04:05PM  
Mar-22-22 06:52AM  
Mar-08-22 04:05PM  
Feb-26-22 06:55AM  
Feb-10-22 03:36PM  
Feb-09-22 04:05PM  
Feb-07-22 04:05PM  
Feb-02-22 04:05PM  
Jan-26-22 09:15AM  
Jan-24-22 06:42PM  
Jan-10-22 07:02AM  
Jan-03-22 07:30AM  
Dec-28-21 09:40AM  
Dec-17-21 10:06AM  
Dec-14-21 09:43AM  
Dec-09-21 10:33AM  
Dec-07-21 12:32PM  
Dec-06-21 10:00AM  
Dec-03-21 10:18AM  
Nov-30-21 04:20PM  
Nov-22-21 10:27AM  
Nov-19-21 12:00PM  
Nov-11-21 10:11AM  
Nov-09-21 04:05PM  
Nov-08-21 10:00AM  
Nov-04-21 03:31AM  
Nov-03-21 04:05PM  
Nov-02-21 09:10AM  
Nov-01-21 07:03AM  
Oct-29-21 12:11PM  
Oct-27-21 04:05PM  
Oct-25-21 07:05AM  
Oct-21-21 12:18PM  
Oct-05-21 04:05PM  
Sep-27-21 02:01PM  
Sep-02-21 04:05PM  
Aug-30-21 02:08PM  
Jul-29-21 08:02PM  
Jul-28-21 04:05PM  
Jul-21-21 04:05PM  
Jun-29-21 10:42AM  
Jun-24-21 07:05AM  
Jun-17-21 09:55AM  
Jun-10-21 04:05PM  
Apr-29-21 12:31AM  
Apr-28-21 04:05PM  
Apr-27-21 08:30AM  
Apr-21-21 04:05PM  
Apr-08-21 12:49PM  
Apr-07-21 04:05PM  
Mar-04-21 04:30PM  
Feb-17-21 10:01PM  
Feb-10-21 04:05PM  
Jan-26-21 07:33AM  
Jan-13-21 05:25AM  
Jan-06-21 04:05PM  
Jan-05-21 04:05PM  
Dec-15-20 05:29PM  
Nov-23-20 10:00AM  
Nov-10-20 04:05PM  
Oct-30-20 05:50AM  
Oct-29-20 03:03AM  
Oct-28-20 04:05PM  
Oct-21-20 04:05PM  
Sep-09-20 07:05AM  
Sep-02-20 04:30PM  
Sep-01-20 07:06PM  
Aug-31-20 08:23AM  
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FOEHR MATTHEW WDirectorMay 02Buy2.4745,000111,195111,250May 03 04:12 PM